The scope of this document is to describe the basis and regulatory requirements for the use of minimal residue disease (MRD) as an intermediate endpoint to predict clinical benefit in trials in chronic lymphocytic leukaemia (CLL). At present, this guidance is not applicable to other clinical settings.


Posted on the EMA website on 15 December 2014